

CDC to hold an "emergency meeting" on rare but "higher-than-expected" reports of heart inflammation following jabs Pfizer/Moderna

Description

CDC to hold an "emergency meeting" on rare but "higher-than-expected" reports of heart inflammation following jabs of the mRNA-based Pfizer and Moderna #COVID19 vaccines (CNBC)

The Centers for Disease Control and Prevention announced Thursday that it will convene an "emergency meeting" of its advisers on June 18th to discuss rare but higher-thanexpected reports of heart inflammation following doses of the mRNA-based Pfizer and Moderna COVID-19 vaccines.

So far, the CDC has identified 226 reports that might meet the agency's "working case definition" of myocarditis and pericarditis following the shots, the agency <u>disclosed Thursday</u>. The vast majority have recovered, but 41 had ongoing symptoms, 15 are still hospitalized, and 3 are in the intensive care unit.

The reports represent just a tiny fraction of the <u>nearly 130 million Americans</u> who have been fully vaccinated with either Pfizer or Moderna's doses.

The CDC previously disclosed that reports of heart inflammation were detected mostly in younger men and teenage boys following their second dose, and that there was a "higher number of observed than expected" cases in 16- to 24-year-olds. Last month, the CDC urged providers to "ask about prior COVID-19 vaccination" in patients with symptoms of heart inflammation.

"Risk-benefit considerations to determine whether to issue an emergency use authorization for use of a COVID-19 vaccine into healthy pediatric individuals will need to account for this information, and risk-benefit consideration will likely be different, not only compared to those for adults, but also they may be different for younger versus older pediatric groups," Dr. Marion Gruber, director of the FDA's vaccine office, said at the meeting.

Date Created 06/14/2021

Page 2